Synergistic Killing and Re-Sensitization of Pseudomonas aeruginosa to Antibiotics by Phage-Antibiotic Combination Treatment

Autor: Emily Engeman, Helen R. Freyberger, Brendan W. Corey, Amanda M. Ward, Yunxiu He, Mikeljon P. Nikolich, Andrey A. Filippov, Stuart D. Tyner, Anna C. Jacobs

Publikováno v: Pharmaceuticals, Vol 14, Iss 3, p 184 (2021)

Multidrug-resistant (MDR) Pseudomonas aeruginosa infections pose a serious health threat. Bacteriophage–antibiotic combination therapy is a promising candidate for combating these infections. A 5-phage P. aeruginosa cocktail, PAM2H, was tested in c

Externí odkaz: https://doaj.org/article/d51e52722db14501aadfee3af03f8332

Neutralizing antibody VRC01 failed to select for HIV-1 mutations upon viral rebound

Autor: Yifan Li, Robert Gramzinski, Eugene Kroon, Donn J Colby, Sandhya Vasan, Nelson L. Michael, Carlo Sacdalan, Nicolas Chomont, John R. Mascola, Merlin L. Robb, Meera Bose, Evan M. Cale, Emily Engeman, Hongjun Bai, Nicole A. Doria-Rose, Eric Sanders-Buell, Nittaya Phanuphak, Rebecca M. Lynch, Daniel Silas, Robert T. Bailer, Brendan Mann, Jintanat Ananworanich, Anne Marie O'Sullivan, Bethany L. Dearlove, Sodsai Tovanabutra, Morgane Rolland, Lydie Trautmann, Trevor A Crowell, Amarendra Pegu, Khunthalee Benjapornpong, Suteeraporn Pinyakorn, Michael A. Messina, Amélie Pagliuzza, Jintana Intasan

Publikováno v: The Journal of Clinical Investigation
Journal of clinical investigation, 130(6), 3299-3304. The American Society for Clinical Investigation

Infusion of the broadly neutralizing antibody VRC01 has been evaluated in individuals chronically infected with HIV-1. Here, we studied how VRC01 infusions affected viral rebound after cessation of antiretroviral therapy (ART) in 18 acutely treated a

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::4cebd0eec2ed6530fdb2e29967e13f77
https://pubmed.ncbi.nlm.nih.gov/32182219